Boey
Authorised
This medicine is authorised for use in the European Union
trenibotulinumtoxinE
MedicineHumanAuthorised
- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
Boey is a medicine used to temporarily improve the appearance of vertical frown lines between the eyebrows. It is used in adults with moderate to severe facial lines when these lines have a significant psychological impact.
Boey contains the active substance trenibotulinumtoxinE.
The medicine can only be obtained with a prescription and should be given by a doctor with the appropriate qualifications and expertise in the treatment of vertical lines between the eyebrows.
Boey is given by injection into the muscles in the forehead whose contractions cause the vertical lines between the eyebrows. The medicine is injected into the muscle in 5 different places above and between the eyebrows.
Boey has an early onset of effect and short duration and should be used occasionally.
For more information about using Boey, see the package leaflet or contact your doctor or pharmacist.
The active substance in Boey, trenibotulinumtoxinE, is produced by the bacterium Clostridium botulinum. The toxin reduces the release of acetylcholine, a chemical messenger that causes muscles to contract. When Boey is injected directly into the muscles above and between the eyebrows, it causes the muscles to relax, helping to make the vertical lines less noticeable.
Boey has been shown to make the vertical lines between the eyebrows less noticeable in two main studies involving 725 adults with moderate or severe vertical lines that affected their mood or caused symptoms of anxiety or depression.
In both studies, Boey was compared with placebo (a dummy treatment). The effectiveness of treatment was measured using a standard 4-point scale, called facial wrinkle scale (FWS), where 0 = no lines, 1 = mild, 2 = moderate and 3 = severe.
Seven days after treatment, 72.6% of adults (386 out of 532) treated with Boey were assessed by the study doctor as having either mild or no vertical lines with at least a 2 grade improvement between the eyebrows, compared with 0.5% (1 out of 193) of those receiving placebo. When asked to assess their own appearance, 63.1% of adults (335 out of 532) reported improvement with Boey, compared with 0.5% (1 out of 193) in the placebo group.
Studies carried out with Boey are described in more detail in the medicine’s assessment report.
For the full list of side effects and restrictions with Boey, see the package leaflet.
The most common side effects with Boey (which may affect up to 1 in 100 people) include drooping eyelids, drooping eyebrows, and in rare cases, Mephisto sign (an exaggerated arching of the eyebrows).
Boey must not be used in people who are hypersensitive (allergic) to any botulinum toxin preparation. It must also not be used in people with diseases affecting the muscles, such as myasthenia gravis or Eaton-Lambert syndrome, and those who have an infection or inflammation at the planned site of injection.
Boey is more effective than placebo in adults with moderate to severe vertical lines between the eyebrows, with a peak effect after 7 days. The observed side effects were generally mild and non-serious and are similar to those seen with other botulinum toxin medicines.
The European Medicines Agency decided that Boey’s benefits are greater than its risks when used occasionally and it can be authorised for use in the EU.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Boey have been included in the summary of product characteristics and the package leaflet.
As for all medicines, data on the use of Boey are continuously monitored. Suspected side effects reported with Boey are carefully evaluated and any necessary action is taken to protect patients.
Boey received a marketing authorisation valid throughout the EU on 15 July 2026.
For information about the availability of this medicine in your country, contact your national competent authority.
Product information
15/07/2026
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Boey
- Active substance
- trenibotulinumtoxinE
- International non-proprietary name (INN) or common name
- trenibotulinumtoxinE
- Therapeutic area (MeSH)
- Stress, Psychological
- Cosmetic Techniques
- Anatomical therapeutic chemical (ATC) code
- Not yet assigned
Pharmacotherapeutic group
- MUSCLE RELAXANTS
- Other muscle relaxants, peripherally acting agents
Therapeutic indication
Boey is indicated for the temporary improvement in the appearance of moderate to severe lines between the eyebrows seen at maximum frown (glabellar lines), when these have an important psychological impact in adult patients.
News on Boey
This page was last updated on